Hypovolaemia; history of severe asthma, severe cardiac disease, severe anaemia, hyperkalaemia, toxaemia, myasthenia gravis, myxoedema; severe renal or hepatic disease; muscular dystrophies, adrenocortical insufficiency; increased intracranial pressure; elderly, pregnancy, lactation. Avoid extravasation or intra-arterial administration. IV inj of concentrated thiopental solution e.g. 5% may cause thrombophloebitis.
Indication
Status epilepticus, Induction of anesthesia, Reduction of raised intracranial pressure
Contra Indication
Thiopental Sodium for Injection is contraindicated in patients with severe respiratory embarrassment, hypersensitivity to barbiturates, status asthmaticus, variegate or acute intermittent porphyria, and inflammatory conditions of the mouth, jaw, and neck and in the absence of suitable veins for intravenous administration. Thiopental Sodium for Injection is also relatively contraindicated in severe cardiovascular disease, hypotension or shock, and conditions in which the hypnotic effect may be prolonged or potentiated, i.e. excessive premedication, Addison's disease, hepatic or renal dysfunction, myxedema, increased blood urea, severe anemia and myasthenia gravis.
Dose
N/A
Side Effect
Coughing, hiccupping, sneezing, muscle twitching, laryngospasm, bronchospasm. IV: tissue necrosis (if extravasation occurs). Intra-arterial: Severe arterial spasm with burning pain, blanching of forearm and hands and gangrene of digits.
Potentially Fatal: Respiratory depression, arrhythmias, circulatory failure and anaphylactoid reactions.
Pregnancy Category
Name :
C
Description
Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks
Mode of Action
Thiopental sodium, a short-acting barbiturate anaesthetic, is a CNS depressant inducing hypnosis and anaesthesia but not analgesia. It has also been used in the control of refractory tonic-clonic status epilepticus and to reduce increased intracranial pressure in neurosurgical patients.
Interaction
Possible increase in difficulty in producing anaesthesia in patients taking alcohol or CNS depressants. Additive action with other CNS depressants including sedatives, hypnotics, nitrous oxide or alcohol. Increased hypotension and excitatory effects with phenothiazine antipsychotics. Increased hypnotic effect with antipsychotic. Decreased requirement of thiopental sodium with metoclopramide, sulfisoxazole, aspirin, meprobamate, probenecid and other highly protein bound drugs.
Potentially Fatal: Increased resp depression with opioids.
Pregnancy Category Note
N/A
Adult Dose
Intravenous
Induction of anaesthesia
Adult: 100-150 mg of a 2.5 or 5% solution injected over 10-15 sec repeated every 30-60 sec according to response or as a continuous infusion of a 0.2 or 0.4% solution. Max: 500mg. Max in pregnancy: 250mg.
Status epilepticus
Adult: In conjunction with assisted ventilation: 75-125 mg as a 2.5% solution.
Reduction of raised intracranial pressure
Adult: Intermittent bolus inj of 1.5-3.5 mg/kg, if adequate ventilation is provided.
Elderly: Dose reduction may be needed.
Hepatic impairment: Dose reduction may be needed.
Child Dose
Intravenous
Induction of anaesthesia
Child: 2-7 mg/kg over 10-15 seconds; repeated after 1 minute if needed..
Status epilepticus
Child: 5 mg/kg by slow IV inj followed by, neonates: continuous iv infusion of 2.5 mg/kg/hr;
>1 month: 2-8 mg/kg/hr. Adjust infusion dose according to response.
Reduction of raised intracranial pressure
Child: 3 mth-15 yr: initial 5-10-mg/kg IV followed by a continuous IV infusion at 1-4 mg/kg/hr.
Renal Dose
Renal impairment: Dose reduction may be needed.
Administration
N/A
Disclaimer
The information provided herein are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please note that this information should not be treated as a replacement for physical medical consultation or advice. Great effort has been placed to provide accurate and comprehensive data. However, Medicart along with its authors and editors make no representations or warranties and specifically disclaim all liability for any medical information provided on the site. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company.